Evome Medical Technologies Inc.
LNDZF · OTC
12/31/2023 | 2/28/2022 | 2/28/2021 | 2/29/2020 | |
|---|---|---|---|---|
| Revenue | $62,627 | $18,312 | -$34 | $352 |
| % Growth | 242% | 54,686.9% | -109.5% | – |
| Cost of Goods Sold | $40,094 | $12,350 | $12,350 | $372 |
| Gross Profit | $22,533 | $5,962 | -$12,384 | -$20 |
| % Margin | 36% | 32.6% | 36,914.6% | -5.8% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $24,156 | $5,728 | $990 | $1,708 |
| SG&A Expenses | $24,156 | $5,728 | $990 | $1,708 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $3,899 | $234 | -$1,644 | $0 |
| Operating Expenses | $28,055 | $5,962 | $990 | $1,708 |
| Operating Income | -$5,522 | -$4,839 | -$1,024 | -$1,689 |
| % Margin | -8.8% | -26.4% | 3,051.9% | -479.5% |
| Other Income/Exp. Net | -$10,024 | $365 | -$1,644 | $338 |
| Pre-Tax Income | -$15,546 | -$4,474 | -$2,667 | -$1,768 |
| Tax Expense | $57 | -$102 | $0 | $613 |
| Net Income | -$15,603 | -$4,372 | -$2,667 | -$2,341 |
| % Margin | -24.9% | -23.9% | 7,951.3% | -664.9% |
| EPS | -0.16 | -0.1 | -0.061 | -0.069 |
| % Growth | -60.3% | -63.7% | 11.8% | – |
| EPS Diluted | -0.16 | -0.1 | -0.061 | -0.069 |
| Weighted Avg Shares Out | 73,472 | 43,627 | 43,627 | 33,785 |
| Weighted Avg Shares Out Dil | 73,472 | 43,627 | 43,627 | 33,785 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $2,640 | $388 | $388 | $0 |
| Depreciation & Amortization | $2,485 | $842 | $842 | $55 |
| EBITDA | -$10,421 | -$3,244 | -$1,438 | -$1,634 |
| % Margin | -16.6% | -17.7% | 4,285.3% | -464.1% |